For research use only. Not for therapeutic Use.
Gimatecan is an investigational oral anticancer agent belonging to the camptothecin family of topoisomerase I inhibitors. It works by stabilizing the complex between topoisomerase I and DNA, preventing the re-ligation of single-strand breaks and ultimately leading to DNA damage and cell death. Gimatecan has shown promise in preclinical and early clinical studies for its potential effectiveness against various solid tumors, including ovarian and lung cancers. Its oral bioavailability and potent antitumor activity make it a candidate for further development in cancer therapy.
| Catalog Number | I006961 |
| CAS Number | 292618-32-7 |
| Synonyms | (19S)-19-ethyl-19-hydroxy-10-[(E)-(2-methylpropan-2-yl)oxyiminomethyl]-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione |
| Molecular Formula | C25H25N3O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H25N3O5/c1-5-25(31)18-10-20-21-16(12-28(20)22(29)17(18)13-32-23(25)30)15(11-26-33-24(2,3)4)14-8-6-7-9-19(14)27-21/h6-11,31H,5,12-13H2,1-4H3/b26-11+/t25-/m0/s1 |
| InChIKey | UIVFUQKYVFCEKJ-OPTOVBNMSA-N |
| SMILES | CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)C=NOC(C)(C)C)O |
